 |
|
| Parkinson's Disease Clinical Trials For posting and discussion of clinical trials related to Parkinson's Disease, and for the Parkinson Pipeline Project. All are welcome. |
| Reply |
|
|
Thread Tools | Display Modes |
|
|
04-14-2013, 03:36 PM
|
#1 | ||
|
|||
|
Senior Member
|
"Thu Apr 11, 2013 9:43am EDT
(Reuters) - Acadia Pharmaceuticals Inc said data from an initial late-stage trial would be sufficient to file for approval for its experimental antipsychotic drug for Parkinson's disease patients, ... Parkinson's disease psychosis is a debilitating disorder that develops in up to 60 percent of patients as their Parkinson's disease progresses. Most current antipsychotic drugs cannot be used in Parkinson's disease patients as they block dopamine in the brain, which is the primary target for Parkinson's therapy, and can lead to a worsening of motor functions in such patients. Pimavanserin works by selectively blocking certain serotonin receptors in the brain, but has no effect on dopamine..." http://www.reuters.com/article/2013/...93A0IA20130411 John
__________________
Born 1955. Diagnosed PD 2005. Meds 2010-Nov 2016: Stalevo(75 mg) x 4, ropinirole xl 16 mg, rasagiline 1 mg Current meds: Stalevo(75 mg) x 5, ropinirole xl 8 mg, rasagiline 1 mg |
||
|
 Reply With Quote
|
| Reply |
|
|
Similar Threads
|
||||
| Thread | Forum | |||
| REBATE CARD: zelaCARD for Parkinson's Disease Patients Taking Zelapar(R) [Selegiline] | Parkinson's Disease | |||
| CLINICAL TRIAL...Phase III Trial with Pimavanserin in Patients with PD Psychosis | Parkinson's Disease Clinical Trials | |||
Hybrid Mode
